Shay Capital’s ACELYRIN SLRN Stock Holding History

Shay Capital’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-78,500	Closed	-$387K	–	417
2024 Q3	$387K	Buy	78,500 +24,000	+44%	+$124K	0.05%	190
2024 Q2	$240K	Buy	54,500 +27,273	+100%	+$128K	0.03%	209
2024 Q1	$184K	Buy	+27,227	New	+$207K	0.03%	303

Other funds holding SLRN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Shay Capital's SLRN Position: Q4 2024 in Review

Shay Capital sold out of ACELYRIN (SLRN) in Q4 2024, closing a stake of 78,500 shares — an estimated $387K sold.

Shay Capital first reported a position in SLRN in Q1 2024 and held it in 3 quarters. The position peaked at $387K in Q3 2024. 125 funds tracked by Wall St. Rank hold SLRN as of Q4 2024.

Shay Capital reported no remaining ACELYRIN position as of Q4 2024 after selling out during the quarter.
Shay Capital sold 78,500 ACELYRIN shares in Q4 2024, an estimated $387K.
Shay Capital first reported a position in ACELYRIN in Q1 2024 and held it in 3 quarters.
Shay Capital's ACELYRIN position peaked at $387K in Q3 2024.
125 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2024.

Based on Shay Capital's 13F filing for Q4 2024, filed 14 Feb 2025.